Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Researchers report progress on non-invasive method to assess kidney function

Researchers report progress on non-invasive method to assess kidney function

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

MD Anderson researcher awarded 2013 Fight Colorectal Cancer-AACR Fellowship

MD Anderson researcher awarded 2013 Fight Colorectal Cancer-AACR Fellowship

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

New study suggests that Ranibizumab can be potential prophylaxis for PVR

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Doctors give new hope for leukemia patients

Doctors give new hope for leukemia patients

AACR recognizes scientists whose contributions to cancer field have extraordinary impact

AACR recognizes scientists whose contributions to cancer field have extraordinary impact

MD Anderson researchers named Fellows to new AACR academy

MD Anderson researchers named Fellows to new AACR academy

Researchers identify monoclonal antibody that directly kills lymphocytic leukemia cells

Researchers identify monoclonal antibody that directly kills lymphocytic leukemia cells

Novel cell therapy effective in treating aggressive form of childhood leukemia

Novel cell therapy effective in treating aggressive form of childhood leukemia

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X advances ARGX-112 into formal preclinical development

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Omalizumab scratches the itch for urticaria patients

Omalizumab scratches the itch for urticaria patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.